TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18583190
Drug: Preoperative chemoradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiation (three cycles of cisplatin and etoposide, followed by twice-daily radiation with concurrent carboplatin and vindesine)
Study: 8956204
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral formulation of melatonin
Study: 1416895
Drug: sulbactam-ampicillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulbactam-ampicillin (4 doses of 3 g ampicillin and 1.5 g sulbactam i.v. every 6 h)
Study: 1416895
Drug: clindamycin-amikacin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: clindamycin-amikacin (4 doses of 600 mg clindamycin i.v. every 6 h and 2 doses of 500 mg amikacin i.v. every 12 h)
Study: 3858547
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) 3 mg/day orally for four days
Study: 24378880
Drug: Group-based acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based acceptance and commitment therapy (GACT)
Study: 24378880
Drug: Recommended pharmacological
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended pharmacological treatment (RPT; pregabalin + duloxetine)
Study: 19278084
Drug: Oscillating/rotating power
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oscillating/rotating power toothbrush (Oral-B Triumph Professional Care 9000)
Study: 8904352
Drug: Dideuterated glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dideuterated glucose as tracer, with non-adapted tracer priming dose
Study: 8904352
Drug: Dideuterated glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dideuterated glucose as tracer, with appropriately matched priming dose
Study: 31373919
Drug: Antiretroviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment (ART) discontinuation
Study: 28863364
Drug: PBdiet (42
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBdiet (42 g various protein sources, n=19)
Study: 28863364
Drug: CBdiet (high‐carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBdiet (high‐carbohydrate breakfast, 17 g protein from various sources, n=18)
Study: 16157010
Drug: COX‐2 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX‐2 inhibitor therapy (Rofecoxib) 25 mg/day for 10 days before surgery
Study: 12825134
Drug: UDCA at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA at 600 mg/day plus bezafibrate at 400 mg/day
Study: 12825134
Drug: UDCA at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA at 600 mg/day (control group)
Study: 10971229
Drug: USA UDCA
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: USA UDCA tablet
Study: 10971229
Drug: Canadian UDCA
Normalized name: Canadian bluegrass pollen extract
DrugBank: Poa compressa pollen (DB10713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canadian UDCA tablet
Study: 10971229
Drug: North American
Normalized name: North American coral snake antivenin
DrugBank: Coral snake (micrurus fulvius) immune globulin antivenin (equine) (DB13883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: North American tablets
Study: 2223345
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.25% bupivacaine plain solution
Study: 2223345
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.25% bupivacaine plain solution
Study: 1458939
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion > 5 micrograms/kg/min for 4 hrs
Study: 30892700
Drug: Neoadjuvant chemoendocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoendocrine therapy (NCET)
Study: 27380504
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (α‐blocker, anti‐inflammatory agent, muscle relaxant)
Study: 27380504
Drug: Combined extracorporeal
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined extracorporeal shock-wave therapy (ESWT) and triple therapy
Study: 24767584
Drug: Strengthening, stretching,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strengthening, stretching, and functional training administered twice a week for 12 weeks to 26 patients.
Study: 24767584
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical care: pharmacological treatment for diabetes and foot care instructions administered to 29 patients.
Study: 22351381
Drug: Lamotrigine 100
Normalized name: lamotrigine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 100 mg/day
Study: 20538187
Drug: NGX‐4010, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGX‐4010, a high‐concentration capsaicin patch (capsaicin 8%)
Study: 14580927
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of inhaled salmeterol (50 microg) (T1)
Study: 14580927
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment with inhaled salmeterol (50 microg bid) for 1 week (T2)
Study: 10544919
Drug: Oral lefradafiban
Normalized name: Lefradafiban
DrugBank: Lefradafiban (DB04863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lefradafiban (the oral prodrug of fradafiban)
Study: 15215800
Drug: Noninvasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive treatment
Study: 6194145
Drug: Acyclovir (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (5 mg/kg)
Study: 8695076
Drug: IV alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV alfentanil (ALF) 10 mcg/kg
Study: 1514331
Drug: No spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: No spray (Control)
Study: 6476334
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg ketamine
Study: 30927644
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation with vitamin C (500 mg/d) and E (400 UI/d) for 15 days
Study: 29991707
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PgE1 and endothelin‐1 blocker (bosentan)
Study: 25593496
Drug: BOACT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOACT group (240 mg bismuth subcitrate, 20 mg omeprazole, 1000 mg amoxicillin, 500 mg clarithromycin, 500 mg tinidazole)
Study: 7522798
Drug: 127I-labeled peptides
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 127I-labeled peptides tested for their ability to displace 125I-T4 binding to thyroid hormone autoantibodies (THAA) in Graves' disease cases.
Study: 7522798
Drug: 125I-labeled peptides
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125I-labeled peptides tested for direct binding to antibodies.
Study: 3028892
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of L‐3H‐NA
Study: 3028892
Drug: L‐3H‐noradrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐3H‐noradrenaline infusion
Study: 29224236
Drug: Primary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary treatment
Study: 23803895
Drug: 2:1 lipid:protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2:1 lipid:protein combination (L2P1)
Study: 23803895
Drug: 1:2 lipid:protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:2 lipid:protein combination (L1P2)
Study: 17625308
Drug: Long-term infusion
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term infusion of gabexate (12 hours)
Study: 17625308
Drug: Short-term infusion
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term infusion of gabexate (2.5 and 6.5 hours)
Study: 17625308
Drug: Short-term administration
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term administration of ulinastatin (10 minutes)
Study: 17625308
Drug: Long-term infusion
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term infusion of gabexate
Study: 11421841
Drug: Ropivacaine, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine, 2 mg x ml(‐1) with continuous infusion of 6 ml x h(‐1) and PCEA bolus doses of 2 ml
Study: 11421841
Drug: Bupivacaine, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine, 2 mg x ml(‐1) with continuous infusion of 6 ml x h(‐1) and PCEA bolus doses of 2 ml
Study: 3126699
Drug: Magnesium hydroxide
Normalized name: Magnesium Hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium hydroxide (25 ml daily)
Study: 11072596
Drug: Oral chicken
Normalized name: Chicken
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chicken type II collagen (CII) at 0.25 mg/day (n = 31)
Study: 31241002
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 g/day Maltodextrin)
Study: 23144810
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D insufficiency (<30 ng/mL)
Study: 23144810
Drug: Serum 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25(OH)D concentrations categorized as <10, 10-20, 20-30, and ≥30 ng/mL
Study: 15752880
Drug: Rectangular or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectangular or conformal fields with a dose of 66 Gy
Study: 10436100
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (plasma homocyst(e)ine level < 7.3 micromol/L)
Study: 21336804
Drug: Anti-platelet drugs
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-platelet drugs
Study: 15088883
Drug: LDD (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDD (20 mg b.i.d.) + AFS
Study: 11531834
Drug: Sirolimus 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus 3.0 mg m(‐2) daily + cyclosporin 1.25 mg kg(‐1) daily
Study: 11531834
Drug: Cyclosporin 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin 5.0 mg kg(‐1) daily
Study: 11531834
Drug: Cyclosporin 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin 1.25 mg kg(‐1) daily
Study: 11531834
Drug: Sirolimus plus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus plus reduced‐dose cyclosporin
Study: 31730369
Drug: Attentional Bias
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attentional Bias Modification Therapy (ABMT)
Study: 30246184
Drug: Non-occluding provisional
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-occluding provisional acrylic reinforced prosthesis within 24 h of implant placement
Study: 16814131
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone replacement therapy (HRT) with continuous oral conjugated equine estrogens (CEE; 0.625 mg/day) plus cyclic oral MPA (2.5 mg/day for 12 days) for 12 months
Study: 12904807
Drug: Apomorphine sublingual
Normalized name: apomorphine Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine sublingual
Study: 18190664
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance treatment
Study: 22683226
Drug: Controlled-release carbamazepine
Normalized name: carbamazepine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release carbamazepine
Study: 29948233
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment (CBT)
Study: 10563033
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment with Nicorette gum
Study: 1812498
Drug: imipramine 75
Normalized name: trimipramine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: imipramine 75 mg
Study: 25280414
Drug: Polyunsaturated fatty
Normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyunsaturated fatty acids (PUFA) intake as percentage of daily energy (median 5.3%)
Study: 20075928
Drug: Candesartan therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan therapy for 6 months
Study: 18503053
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) levels in follicular fluids
Study: 27572327
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg triamcinolone hexacetonide (TH)
Study: 27572327
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone (DEX)
Study: 25202955
Drug: Ambroxol (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (1,000 mg/d on the day of operation and on the first 3 postoperative days)
Study: 11876581
Drug: Completion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completion of full treatment
Study: 10655905
Drug: Dexmedetomidine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.6 ng ml‐1)
Study: 10655905
Drug: Placebo (0.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.0 ng ml‐1)
Study: 19233534
Drug: 6% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydrogen peroxide whitening strips used twice daily for 30 minutes over a 2-week period
Study: 1837130
Drug: UW solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: UW solution
Study: 7678358
Drug: UW-mod solution
Normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: UW-mod solution
Study: 29614991
Drug: Complete administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete administration of chemotherapy cycles
Study: 29614991
Drug: Incomplete administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incomplete administration of chemotherapy cycles
Study: 31888732
Drug: Medication Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Therapy Management (MTM) intervention
Study: 11700852
Drug: Testosterone Enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone Enanthate (TE) 100 mg weekly
Study: 11700852
Drug: Testosterone Enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone Enanthate (TE) 25 mg weekly
Study: 11700852
Drug: Testosterone Enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone Enanthate (TE) 50 mg weekly
Study: 11700852
Drug: Testosterone Enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone Enanthate (TE) 100 mg and 300 mg weekly
Study: 9221556
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TENS and tactile stimulation
Study: 7636643
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (3 mg of Zn acetate per day)
Study: 2539764
Drug: Nedocromil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedocromil (2 puffs of 2 mg/puff)
Study: 911607
Drug: Warning labels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warning labels showing drugs known to interact
Study: 30341969
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing of PPI
Study: 30341969
Drug: Genotype-guided dosing
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided dosing of PPI
Study: 27465372
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g fiber from SCF/d
Study: 25660414
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid supplementation twice daily
Study: 25660414
Drug: Placebo supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplementation twice daily
Study: 18684664
Drug: Optimal pharmacological
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal pharmacological treatment
Study: 12816824
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (0.05% cream or 0.005% ointment) applied twice weekly
Study: 12816824
Drug: Emollient alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient alone (placebo) applied twice weekly
Study: 12816824
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate cream applied twice weekly
Study: 9254261
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no perftoran infusion)
Study: 3297907
Drug: Paracentesis (4-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracentesis (4-6 L/day until disappearance of ascites) and intravenous albumin infusion (40 g after each tap)
Study: 29231409
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection of salmon calcitonin (100 U, 4 mL total, 1 mL per acupoint)
Study: 29231409
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of salmon calcitonin (100 U)
Study: 29231409
Drug: Blank group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank group (0.9% sodium chloride injection, 1 mL per acupoint)
Study: 7926494
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg once daily
Study: 16868803
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg or 20 mg
Study: 27296366
Drug: Group-based outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based outpatient physiotherapy intervention (1-hour class weekly for 6 weeks)
Study: 18703875
Drug: Evidence-based algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based algorithm treatment
Study: 18703875
Drug: Algorithm treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm treatment
Study: 16462914
Drug: Rofecoxib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (50 mg, daily)
Study: 16462914
Drug: Tramadol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (50 mg, 3 times per day)
Study: 10872103
Drug: Generic pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic pentoxifylline sustained-release (SR) tablet
Study: 8803512
Drug: Glutamine (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (Group G)
Study: 19240374
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Th221 (60 mg/day)
Study: 19240374
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Th221 (20.4 mg/day)
Study: 17960962
Drug: Risperidone 3
Normalized name: risperidone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 3 mg b.i.d.
Study: 15909856
Drug: Regimen I
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen I (standard high dose regimen) - 100 ml ASV loading dose followed by 50 ml every six hours
Study: 15909856
Drug: Regimen II
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen II - 30 ml ASV loading dose followed by 30 ml continuous infusion every six hours
Study: 9585823
Drug: OM-85-BV (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM-85-BV (3.5 mg of bacterial extracts)
Study: 23791153
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (800 μg)
Study: 14572570
Drug: Relaxation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation Therapy
Study: 11084571
Drug: Long-term oral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oral contraceptive use
Study: 30144429
Drug: Obeticholic Acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic Acid (OCA) 10 mg/kg for 2 weeks in mice
Study: 26563519
Drug: Topical recombinant
Normalized name: thrombin topical recombinant 5000 intl units topical powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical recombinant human epidermal growth factor (EGF) cream
Study: 12722031
Drug: Low-dose prednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisolone therapy (initial dose of 20 mg/d, tapered to 5 mg/d over 2 years)
Study: 22616078
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no steroid treatment)
Study: 12722031
Drug: Low-dose prednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisolone therapy
Study: 8979658
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate in solution (TS) 0.5 percent